RE:13 & 14fredgoodwinson wrote: Patients 13 & 14 will be our patients 5 & 6 (i.e.optimally dosed - this time twice).
They may well already have 30-day data for one of them. Only 37 days` after P.6`s single treatment they were able to pronounce:
‘To date the patient has shown no evidence or presence of disease’ This was interpreted as them having confidence at a very early stage (correctly as it turned out) of an enduring complete response.
So there may well be highly price sensitive already available from these recent treatments .Whether they feel inclined or able to publish it independently from the results of the second treatments remains to be seen - probably not.
Even so and although statistically insignificant for many of us these two will be the acid test for the NMIBC Trial. Some time in June?
I know little steps are important, but the ultimate litmus test for me is having whatever amount of data that can lead to a breakthrough therapy designation. Considering additional data from our Covid-19 & Roswell research teams continue to shine, such a designation would "seriously" trigger Big Pharma interest, not to mention possibly decrease trial time by "another" 6 to 12 months. JMO.